Combining CAR-T cells and inhibitor drugs for high-risk neuroblastoma

Chimeric antigen receptor (CAR)-T cell therapy is a promising treatment for cancer, but it is not always effective in neuroblastoma, a deadly childhood cancer. Researchers have found that combining CAR-T cells with an ALK inhibitor drug can enhance the therapy’s effectiveness by increasing the number of targets for the CAR-T cells to attack. In preclinical studies, this combination has shown promising results in reducing tumor growth and improving survival in mice. Clinical trials are being planned to test this combination therapy in children with refractory or relapsed neuroblastoma, offering hope for more effective treatments for this challenging disease.

Source link

error: Content is protected !!